SG11201809527UA - Methods of treating circadian rhythm sleep disorders - Google Patents
Methods of treating circadian rhythm sleep disordersInfo
- Publication number
- SG11201809527UA SG11201809527UA SG11201809527UA SG11201809527UA SG11201809527UA SG 11201809527U A SG11201809527U A SG 11201809527UA SG 11201809527U A SG11201809527U A SG 11201809527UA SG 11201809527U A SG11201809527U A SG 11201809527UA SG 11201809527U A SG11201809527U A SG 11201809527UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- vehicle
- methods
- october
- pct
- Prior art date
Links
- 208000019888 Circadian rhythm sleep disease Diseases 0.000 title abstract 2
- 102220240796 rs553605556 Human genes 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000001788 irregular Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 230000008454 sleep-wake cycle Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Anesthesiology (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662335599P | 2016-05-12 | 2016-05-12 | |
| US201662335611P | 2016-05-12 | 2016-05-12 | |
| US201662413976P | 2016-10-27 | 2016-10-27 | |
| US201662414606P | 2016-10-28 | 2016-10-28 | |
| US201662414599P | 2016-10-28 | 2016-10-28 | |
| PCT/US2017/032228 WO2017197160A1 (en) | 2016-05-12 | 2017-05-11 | Methods of treating circadian rhythm sleep disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201809527UA true SG11201809527UA (en) | 2018-11-29 |
Family
ID=58745465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201809527UA SG11201809527UA (en) | 2016-05-12 | 2017-05-11 | Methods of treating circadian rhythm sleep disorders |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11096941B2 (https=) |
| EP (2) | EP4056180A1 (https=) |
| JP (2) | JP6888026B2 (https=) |
| KR (2) | KR102511855B1 (https=) |
| CN (1) | CN109640998A (https=) |
| AU (3) | AU2017264871B2 (https=) |
| CA (1) | CA3022068A1 (https=) |
| ES (1) | ES2904625T3 (https=) |
| IL (2) | IL291791B2 (https=) |
| MX (1) | MX379318B (https=) |
| MY (1) | MY199382A (https=) |
| RU (1) | RU2763493C2 (https=) |
| SG (1) | SG11201809527UA (https=) |
| TW (1) | TWI795359B (https=) |
| WO (1) | WO2017197160A1 (https=) |
| ZA (1) | ZA201807903B (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11096941B2 (en) * | 2016-05-12 | 2021-08-24 | Eisai R&D Management Co.. Ltd. | Methods of treating circadian rhythm sleep disorders |
| BR112021026291A2 (pt) * | 2019-06-26 | 2022-03-03 | Eisai R&D Man Co Ltd | Lemborexant para tratar problemas de sono |
| JP2022538170A (ja) * | 2019-06-26 | 2022-08-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 睡眠問題の治療のためのレンボレキサント |
| WO2020263253A1 (en) * | 2019-06-26 | 2020-12-30 | Moline Margaret | Lemborexant for treating sleep issues |
| JP7573015B2 (ja) * | 2019-09-13 | 2024-10-24 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 不眠症治療用医薬組成物 |
| JP2023506025A (ja) * | 2019-12-11 | 2023-02-14 | テバ チェコ インダストリーズ エス．アール．オー． | レンボレキサントの固体形態 |
| MX2022008260A (es) * | 2020-01-16 | 2022-08-04 | Eisai R&D Man Co Ltd | Sustancia farmacologica de lemborexant y composicion medicinal que la comprende. |
| CN111450076A (zh) * | 2020-05-25 | 2020-07-28 | 安徽省逸欣铭医药科技有限公司 | 一种Lemborexant软胶囊组合物及其制备方法 |
| CN114159568B (zh) * | 2020-09-11 | 2025-08-01 | 北京原基华毅生物科技有限公司 | Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用 |
| WO2023007320A1 (en) * | 2021-07-26 | 2023-02-02 | Eisai R&D Mangement Co., Ltd. | Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases |
| CN116421605B (zh) * | 2022-01-04 | 2024-08-02 | 中国科学院脑科学与智能技术卓越创新中心 | Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用 |
| WO2024064897A1 (en) | 2022-09-23 | 2024-03-28 | Eisai R&D Management Co., Ltd. | Methods of reducing neurodegeneration associated with neurodegenerative diseases |
| CN121646412A (zh) | 2023-08-08 | 2026-03-10 | 株式会社明治 | 昼夜节律的调整 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06009377A (es) * | 2004-02-20 | 2007-03-07 | Lifescape Biosciences Inc | Composiciones y metodos para regulacion del sueno. |
| ATE458740T1 (de) * | 2006-08-28 | 2010-03-15 | Actelion Pharmaceuticals Ltd | 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten |
| AU2011304285B2 (en) | 2010-09-22 | 2015-01-29 | Eisai R&D Management Co., Ltd. | Cyclopropane compound |
| CA2863413A1 (en) * | 2012-02-07 | 2013-08-15 | Eolas Therapeutics, Inc. | Substituted prolines / piperidines as orexin receptor antagonists |
| ES2843952T3 (es) | 2014-10-23 | 2021-07-21 | Eisai R&D Man Co Ltd | Composiciones para tratar el insomnio |
| US11096941B2 (en) * | 2016-05-12 | 2021-08-24 | Eisai R&D Management Co.. Ltd. | Methods of treating circadian rhythm sleep disorders |
-
2017
- 2017-05-11 US US16/300,335 patent/US11096941B2/en active Active
- 2017-05-11 MY MYPI2018002456A patent/MY199382A/en unknown
- 2017-05-11 IL IL291791A patent/IL291791B2/en unknown
- 2017-05-11 WO PCT/US2017/032228 patent/WO2017197160A1/en not_active Ceased
- 2017-05-11 EP EP21208238.2A patent/EP4056180A1/en active Pending
- 2017-05-11 EP EP17725084.2A patent/EP3454859B1/en active Active
- 2017-05-11 KR KR1020187035708A patent/KR102511855B1/ko active Active
- 2017-05-11 MX MX2018013663A patent/MX379318B/es unknown
- 2017-05-11 AU AU2017264871A patent/AU2017264871B2/en active Active
- 2017-05-11 JP JP2018558728A patent/JP6888026B2/ja active Active
- 2017-05-11 CA CA3022068A patent/CA3022068A1/en active Pending
- 2017-05-11 CN CN201780039758.8A patent/CN109640998A/zh active Pending
- 2017-05-11 SG SG11201809527UA patent/SG11201809527UA/en unknown
- 2017-05-11 KR KR1020237009013A patent/KR20230043227A/ko not_active Ceased
- 2017-05-11 ES ES17725084T patent/ES2904625T3/es active Active
- 2017-05-11 RU RU2018143809A patent/RU2763493C2/ru active
- 2017-05-12 TW TW106115904A patent/TWI795359B/zh active
-
2018
- 2018-11-06 IL IL262803A patent/IL262803B/en unknown
- 2018-11-22 ZA ZA2018/07903A patent/ZA201807903B/en unknown
-
2021
- 2021-05-19 JP JP2021084719A patent/JP7150096B2/ja active Active
- 2021-07-27 US US17/443,650 patent/US20210353625A1/en active Pending
-
2023
- 2023-05-31 AU AU2023203418A patent/AU2023203418A1/en not_active Abandoned
-
2025
- 2025-07-10 AU AU2025205336A patent/AU2025205336A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201809527UA (en) | Methods of treating circadian rhythm sleep disorders | |
| SG11201804814YA (en) | Materials and methods for delivering nucleic acids to cochlear and vestibular cells | |
| SG11201805828YA (en) | Method of treating c3 glomerulopathy | |
| SG11201805570WA (en) | Systems and methods for long term transdermal administration | |
| SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201903032SA (en) | Methods and compositions related to nk cell and anti-pdl1 cancer therapies | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201906161VA (en) | Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells | |
| SG11201811290VA (en) | Compositions and methods for the depletion of cd117+cells | |
| SG11201805888SA (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
| SG11201901834WA (en) | Micrornas as biomarkers for endometriosis | |
| SG11201805162VA (en) | Plasmid constructs for heterologous protein expression and methods of use | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201907196YA (en) | Composition and methods for preventing radiation injury and promoting tissue regeneration | |
| SG11201807041PA (en) | Improved preparations of adult liver progenitor cells | |
| SG11201408808WA (en) | Method and system for treatment of biological tissue | |
| SG11201903076QA (en) | Carbamoyl phenylalaninol compounds and uses therof | |
| SG11201807250PA (en) | Treatment of muscular disorders with combinations of rxr agonists and thyroid hormones | |
| SG11201805771XA (en) | Systems and methods for preparation of platelets | |
| SG11201805052YA (en) | Therapeutic methods using erythrocytes | |
| SG11201803816RA (en) | Targeting of the formyl-peptide receptor 2/lipoxin a4 receptor (fpr2/alx) for treatment of heart disease | |
| SG11201804220SA (en) | Activated stem cells and systemic treatment methods for infected wounds | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |